[go: up one dir, main page]

JOP20190243A1 - علاج الربو بجسم مضاد لـ tslp - Google Patents

علاج الربو بجسم مضاد لـ tslp

Info

Publication number
JOP20190243A1
JOP20190243A1 JOP/2019/0243A JOP20190243A JOP20190243A1 JO P20190243 A1 JOP20190243 A1 JO P20190243A1 JO P20190243 A JOP20190243 A JO P20190243A JO P20190243 A1 JOP20190243 A1 JO P20190243A1
Authority
JO
Jordan
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
JOP/2019/0243A
Other languages
English (en)
Inventor
Jane R Parnes
Janet Griffiths
Original Assignee
Medimmune Llc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Amgen Inc filed Critical Medimmune Llc
Publication of JOP20190243A1 publication Critical patent/JOP20190243A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الكشف الحالي، على نحو عام، بطرق لمعالجة الربو، بما في ذلك الربو الحاد والربو الأيزونوفيلي، باستخدام جسم مضاد نوعي تجاه اللمفوبويتين السدوي السعتري (TSLP).
JOP/2019/0243A 2017-04-12 2017-06-16 علاج الربو بجسم مضاد لـ tslp JOP20190243A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01

Publications (1)

Publication Number Publication Date
JOP20190243A1 true JOP20190243A1 (ar) 2019-10-13

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0243A JOP20190243A1 (ar) 2017-04-12 2017-06-16 علاج الربو بجسم مضاد لـ tslp

Country Status (22)

Country Link
US (3) US10828365B2 (ar)
EP (1) EP3609917A1 (ar)
JP (4) JP7330896B2 (ar)
KR (2) KR102666879B1 (ar)
CN (1) CN110573525A (ar)
AU (2) AU2018253118B2 (ar)
BR (1) BR112019021482A2 (ar)
CA (1) CA3059364A1 (ar)
CL (1) CL2019002897A1 (ar)
CO (1) CO2019011462A2 (ar)
IL (1) IL269791B (ar)
JO (1) JOP20190243A1 (ar)
MX (1) MX2019012158A (ar)
MY (1) MY207509A (ar)
PE (1) PE20200484A1 (ar)
PH (1) PH12019502331A1 (ar)
SG (1) SG11201909322VA (ar)
TN (1) TN2019000289A1 (ar)
TW (2) TWI856945B (ar)
UA (1) UA130334C2 (ar)
UY (1) UY37676A (ar)
WO (1) WO2018191479A1 (ar)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018003038A (es) * 2015-09-09 2018-04-11 Novartis Ag Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MX2021014804A (es) 2019-06-04 2022-01-18 Jiangsu Hengrui Medicine Co Anticuerpo capaz de unirse a la linfopoyetina estromal timica y el uso del mismo.
WO2021007533A1 (en) 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
WO2021043221A1 (en) * 2019-09-04 2021-03-11 Biosion Inc. Antibodies binding tslp and uses thereof
HUE071069T2 (hu) * 2019-10-28 2025-07-28 Medimmune Ltd Tímusz sztrómális limfopoietint (TSLP) kötõ antitestek szárazpor készítményei és eljárások ezek alkalmazására
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
EP4047019A4 (en) * 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTI-TSLP ANTIBODIES AND USES THEREOF
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US20230073888A1 (en) * 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
CA3166964A1 (en) * 2020-02-13 2021-08-19 Alexis Lueras Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
CA3167975A1 (en) * 2020-02-18 2021-08-26 Amgen, Inc. Formulations of human anti-tslp antibodies and methods of using the same
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
JP2024512267A (ja) * 2021-03-03 2024-03-19 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 抗ｔｓｌｐ抗体を含む医薬組成物
JP2024516962A (ja) * 2021-04-19 2024-04-18 メドイミューン・リミテッド 安定性が改善された抗ＴＳＬＰ Ｆａｂ
CA3216700A1 (en) 2021-04-23 2022-10-27 Amgen Inc. Modified anti-tslp antibodies
JP2024517418A (ja) 2021-04-23 2024-04-22 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体組成物及びその使用
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
TW202523697A (zh) * 2023-08-25 2025-06-16 美商普羅特歐拉吉克適美國公司 抗ｔｓｌｐ抗體構築體及其用途
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
BR112012010707B1 (pt) 2009-11-04 2022-08-30 Merck Sharp & Dohme Corp Anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, e, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
EP3177322A4 (en) * 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Also Published As

Publication number Publication date
UY37676A (es) 2018-10-31
CN110573525A (zh) 2019-12-13
US20250032608A1 (en) 2025-01-30
WO2018191479A1 (en) 2018-10-18
KR102666879B1 (ko) 2024-05-23
BR112019021482A2 (pt) 2020-05-12
UA130334C2 (uk) 2026-01-28
US20180296669A1 (en) 2018-10-18
JP2025170430A (ja) 2025-11-18
EP3609917A1 (en) 2020-02-19
US10828365B2 (en) 2020-11-10
JP2024150751A (ja) 2024-10-23
KR20240070727A (ko) 2024-05-21
AU2018253118B2 (en) 2025-04-10
AU2025204735A1 (en) 2025-07-17
JP2023099233A (ja) 2023-07-11
AU2018253118A1 (en) 2019-10-24
TW202523688A (zh) 2025-06-16
JP7330896B2 (ja) 2023-08-22
SG11201909322VA (en) 2019-11-28
JP2020516647A (ja) 2020-06-11
MY207509A (en) 2025-02-28
IL269791B (en) 2022-07-01
CA3059364A1 (en) 2018-10-18
US20210052726A1 (en) 2021-02-25
MX2019012158A (es) 2019-12-16
IL269791A (en) 2019-11-28
CL2019002897A1 (es) 2020-03-06
TWI856945B (zh) 2024-10-01
PH12019502331A1 (en) 2020-09-28
TW201838652A (zh) 2018-11-01
PE20200484A1 (es) 2020-03-03
KR20190140956A (ko) 2019-12-20
CO2019011462A2 (es) 2019-10-31
TN2019000289A1 (en) 2021-05-07

Similar Documents

Publication Publication Date Title
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
MY210545A (en) Chimeric receptors to flt3 and methods of use thereof
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
MY205760A (en) Humanized antibodies against c-kit
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
TN2018000076A1 (en) Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
NZ746609A (en) Ilt7 binding molecules and methods of using the same
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
ZA202205936B (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
PH12020550023A1 (en) Compositions for treating stress-related disorders
MY192390A (en) Method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof
MY201744A (en) Binding polypeptides and methods of making the same
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
MX2025008918A (es) Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp
MX2025013757A (es) Tratamiento para el asma dependiente de corticosteroides con anticuerpo anti-tslp
MX2010007355A (es) Extracto de heteropterys brachiata, metodo de obtencion y uso para el tratamiento de ansiedad y depresion.